RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Simvastatin (drug) (INACTIVE)

A collection of news and information related to Simvastatin (drug) (INACTIVE) published by this site and its partners.

Top Simvastatin (drug) (INACTIVE) Articles see all

Displaying items 1-5
  • FDA bars medications made by Indian generics giant Ranbaxy

    FDA bars medications made by Indian generics giant Ranbaxy
    The Food & Drug Administration on Monday barred the import of any medications made at the premier manufacturing plant of one of the world's largest makers of generic medications, Ranbaxy Laboratories Ltd.
  • The FDA cautions against high doses of Zocor (simvastatin), urges label changes

     
    The highest doses of the cholesterol-lowering drug Zocor produce an increased risk of muscle damage, the Food and Drug Administration cautioned Friday. The risk is highest in patients of Chinese descent and is also high when Zocor, known generically as...

    Vytorin trial shows little or no benefit against heart disease [Updated]

     
    For the second time in as many years, a large clinical trial has found that the key ingredient in the heavily advertised drug Vytorin provides little or no benefit in preventing heart disease compared to a competing product. The ingredient...

    FDA panel says Vytorin and Zetia probably don't cause cancer

     
    A comprehensive review of previous studies involving the cholesterol-lowering drugs Vytorin and Zetia and two large ongoing studies shows that "it is unlikely that [they] increase the risk of cancer or cancer-related deaths," a Food and Drug...

    Even the most common medications pose threats

    Even the most common medications pose threats
    Some drugs are so common that consumers -- at their peril -- don't think twice about them. But each drug, whether prescription or over-the-counter, poses risks. To highlight these risks, we offer up a few details on five of the most-prescribed...